1. Home
  2. NKTR vs LUNG Comparison

NKTR vs LUNG Comparison

Compare NKTR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$69.12

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.87

Market Cap

97.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKTR
LUNG
Founded
1990
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
97.1M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
NKTR
LUNG
Price
$69.12
$1.87
Analyst Decision
Strong Buy
Buy
Analyst Count
7
7
Target Price
$146.67
$5.38
AVG Volume (30 Days)
509.5K
395.5K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$307,711,000.00
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
86.00
8.01
52 Week Low
$33.40
$1.13
52 Week High
$109.00
$2.89

Technical Indicators

Market Signals
Indicator
NKTR
LUNG
Relative Strength Index (RSI) 44.65 38.64
Support Level $70.24 $1.20
Resistance Level $76.49 $2.49
Average True Range (ATR) 2.88 0.15
MACD -0.31 -0.08
Stochastic Oscillator 15.34 7.74

Price Performance

Historical Comparison
NKTR
LUNG

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: